These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 34326951)

  • 1. Current cancer therapies and their influence on glucose control.
    Yim C; Mansell K; Hussein N; Arnason T
    World J Diabetes; 2021 Jul; 12(7):1010-1025. PubMed ID: 34326951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management.
    Khan KH; Wong M; Rihawi K; Bodla S; Morganstein D; Banerji U; Molife LR
    Oncologist; 2016 Jul; 21(7):855-60. PubMed ID: 27151652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
    J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Severe Case of Diabetic Ketoacidosis and New-Onset Type 1 Diabetes Mellitus Associated with Anti-Glutamic Acid Decarboxylase Antibodies Following Immunotherapy with Pembrolizumab.
    Kedzior SK; Jacknin G; Hudler A; Mueller SW; Kiser TH
    Am J Case Rep; 2021 Jun; 22():e931702. PubMed ID: 34185763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR inhibitors and diabetes.
    Vergès B; Cariou B
    Diabetes Res Clin Pract; 2015 Nov; 110(2):101-8. PubMed ID: 26421362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-Centered Diabetes Care of Cancer Patients.
    Kotwal A; Cheung YM; Cromwell G; Drincic A; Leblebjian H; Quandt Z; Rushakoff RJ; McDonnell ME
    Curr Diab Rep; 2021 Dec; 21(12):62. PubMed ID: 34902069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes.
    Lam KS; Chow CC; Tan KC; Ma RC; Kong AP; Tong PC; Tsang MW; Chan TM; Tang SC; Lee KK; So WY; Tomlinson B
    Curr Med Res Opin; 2016 Jun; 32(6):1097-108. PubMed ID: 26933918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute Hyperglycemia Associated with Anti-Cancer Medication.
    Hwangbo Y; Lee EK
    Endocrinol Metab (Seoul); 2017 Mar; 32(1):23-29. PubMed ID: 28345313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
    Pratley RE; Salsali A
    Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drugs and hyperglycemia: A practical guide.
    Jain V; Patel RK; Kapadia Z; Galiveeti S; Banerji M; Hope L
    Maturitas; 2017 Oct; 104():80-83. PubMed ID: 28923179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. When therapeutic drugs lead to diabetes.
    Fève B; Scheen AJ
    Diabetologia; 2022 May; 65(5):751-762. PubMed ID: 35244742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EADSG Guidelines: Insulin Therapy in Diabetes.
    Silver B; Ramaiya K; Andrew SB; Fredrick O; Bajaj S; Kalra S; Charlotte BM; Claudine K; Makhoba A
    Diabetes Ther; 2018 Apr; 9(2):449-492. PubMed ID: 29508275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy.
    Shlomai G; Neel B; LeRoith D; Gallagher EJ
    J Clin Oncol; 2016 Dec; 34(35):4261-4269. PubMed ID: 27903154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management.
    Goldman JW; Mendenhall MA; Rettinger SR
    Oncologist; 2016 Nov; 21(11):1326-1336. PubMed ID: 27473045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review.
    Hong AR; Yoon JH; Kim HK; Kang HC
    Front Endocrinol (Lausanne); 2020; 11():14. PubMed ID: 32047478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperglycemic, high anion-gap metabolic acidosis in patients receiving SGLT-2 inhibitors for diabetes management.
    Kum-Nji JS; Gosmanov AR; Steinberg H; Dagogo-Jack S
    J Diabetes Complications; 2017 Mar; 31(3):611-614. PubMed ID: 27913012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma.
    Changizzadeh PN; Mukkamalla SKR; Armenio VA
    J Immunother Cancer; 2017 Dec; 5(1):97. PubMed ID: 29254501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab.
    Busaidy NL; LoRusso P; Lawhorn K; Hess KR; Habra MA; Fu S; Hong DS; Chen HX; Doyle LA; Kurzrock R; Naing A
    Oncologist; 2015 Jul; 20(7):737-41. PubMed ID: 26054632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitor- and phosphatidylinositol-3-kinase inhibitor-related diabetes induced by antineoplastic drugs: two case reports and a literature review.
    Gao Y; Zhong M; Gan L; Xiang C; Li L; Yan Y
    Front Endocrinol (Lausanne); 2023; 14():1236946. PubMed ID: 37732122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperglycemia and antipsychotic medications.
    Haupt DW; Newcomer JW
    J Clin Psychiatry; 2001; 62 Suppl 27():15-26; discussion 40-1. PubMed ID: 11806485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.